Skip to content
OpenCapital
Get started

Atea Pharmaceuticals, Inc. AVIR Q4 2025 Annual earnings

Reported March 5, 2026 · After market close

Diluted EPS-$0.57Miss by $0.08
Revenue estimate$1.5M
EPS estimate-$0.49

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$33.0M
EPS estimate-$0.56

Versus estimates

Diluted EPS

Q1 2026-$0.57Beat by $0.03
Q4 2025-$0.57Miss by $0.08
Q3 2025-$0.53Miss by $0.07Q2 2025-$0.44Beat by $0.02Q1 2025-$0.40Beat by $0.16Q4 2024-$0.40Miss by $0.05

Ask the moment Atea Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Atea Pharmaceuticals, Inc. report Q4 2025 earnings?
Atea Pharmaceuticals, Inc. (AVIR) reported Q4 2025 earnings on March 5, 2026 after market close.
What were Atea Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.57 for Q4 2025.
Did Atea Pharmaceuticals, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.49 by $0.08.
How did Atea Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 42.5% from $-0.40.
Where can I find Atea Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-093961) and the 10-K periodic report (0001193125-26-094159) directly on SEC EDGAR. The filing index links above go to sec.gov.